Large SPORE Grant Focuses on Developing Biomarkers to Predict Melanoma Immunotherapy Treatment Outcomes

Source: NYU Langone Health, December 2019

The National Cancer Center Institute (NCI) has awarded NYU Langone Health a 5-year, $11 million grant to develop better tools to predict which patients with advanced melanoma will benefit from immune checkpoint inhibitors. The Ronald O. Perelman Department of Dermatology and Perlmutter Cancer Center are using the grant for four distinct and promising projects.

The grant is NYU Langone’s first to be funded by the NCI’s P50 Specialized Programs of Research Excellence (SPORE). The programs promote interdisciplinary investigations to help move findings quickly from laboratory to patient care.

Urgent Need for Biomarkersa